Interested in being a part of the Diagnostic Revolution? Learn more about investment opportunities here.


The Evolution Of Aptamer Technology

The basis for our Q-LAAD technology platform are our revolutionary fluorogenic-logic aptamers (FLAs) which can be programed to signal the presence of nearly any target molecule. The result being a revolutionary new mechanism for the detection of the viruses that cause disease. This mechanism enables the creating of diagnostic tests that combine hospital-grade accuracy with point-of-care speed and ease of use.

Chart iconBe a part of the revolution

We are currently raising capital via a Regulatory A+ securities offering. As an early-stage investor, you can help Facible revolutionize diagnostic testing for people around the world. For a limited time, early investors have the opportunity to earn one bonus share for every share purchased.

Invest Now

Do you have questions about Facible? Read our FAQs below

What is Q-LAAD?

Q-LAAD stands for Quantum-Logic Aptamer Analyte Detection and it is our patent-pending technology we’ve been developing over the past 6 years. Q-LAAD is an antigen detection system that uses aptamer technology to reveal the presence of viral antigens. Q-LAAD can be adapted to nearly any diagnostic testing format without sacrificing speed, accuracy, or ease-of-use, a common tradeoff with current diagnostic testing technologies.

How do Q-LAAD tests work?

Q-LAAD technology enables a fluorogenic logic aptamer to cause a dim fluorophore to become bright only when the aptamer is bound to the intended target.

How is Q-LAAD different than other biodiagnostic tests such as PCR, Isothermal Amplification, ELISA, etc.?

Q-LAAD tests differ from other testing methodologies in a few important ways:

  1. Q-LAAD tests are sensitive enough to detect even trace amounts of a given target molecule, so there is no time-consuming amplification required to see results. Therefore, results from Q-LAAD tests are near-instantaneous.
  2. Q-LAAD tests are specific enough to work with various types of samples and sample collection media such as blood, saliva, urine, etc.
  3. Q-LAAD tests are much simpler and easier to use than other biodiagnostic tests, minimizing the margin for user and/or machine error.
Do Q-LAAD tests require any special, costly equipment?

No. Q-LAAD tests can be run on commercially available COMS analyzers and plate readers. We are currently working on our own point-of-care analyzer which will make Q-LAAD tests even more efficient and easy to use.

Why is Q-LAAD a better testing method for COVID-19?

We have developed a SARS-CoV-2 proof-of-concept test that has shown very promising results in our own clinical trials. Our Q-LAAD SARS-CoV-2 test excelled in three key areas:

  1. Accuracy: : Q-LAAD tests meet or exceed a minimum threshold of 95% accuracy putting it on par with the most accurate (PCR) tests currently available.
  2. Speed: Q-LAAD tests routinely deliver results in less than 5 minutes (and often near instantly) without sacrificing accuracy.
  3. Throughput: Q-LAAD tests require minimal preparation and or specialized training. and can be run on a standard plate reader in minutes enabling technicians to process hundreds of tests in an hour.
What are the applications for Q-LAAD tests?

We are currently adapting our Q-LAAD platform to develop a 30+ pathogen respiratory testing panel that will allow healthcare professionals to quickly diagnose and treat the most common diseases such as influenza, SARS-CoV-2, human metapneumovirus, RSV, etc. In addition to a variety of medical diagnostic tests, we will be developing Q-LAAD tests for use across a wide range of industries including Agricultural, Regulatory, Pharmaceutical, and Veterinary just to name a few.

Are you guys crazy?

Nope. Not crazy. Just audacious.

Didn't find the answer to your question? Don't hesitate to contact us.

Email icon Stay Informed.

Would you like to know more about Facible, our revolutionary technology, partnership opportunities or how you can purchase our products? Sign up on our email list to receive the latest news and announcements.